AC Immune
ACIU
43 hedge funds and large institutions have $58.2M invested in AC Immune in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 16 reducing their positions, and 10 closing their positions.
0.7% less ownership
Funds ownership: 24.74% → 24.04% (-0.7%)
9% less funds holding
Funds holding: 47 → 43 (-4)
25% less call options, than puts
Call options by funds: $212K | Put options by funds: $283K
38% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 16
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
60% less capital inflows, than outflows
Capital inflows: $1.33M | Capital outflows: $3.28M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$594K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$254K |
| 3 |
Two Sigma Investments
New York
|
+$176K |
| 4 |
Morgan Stanley
New York
|
+$117K |
| 5 |
VA
Verdad Advisers
Boston,
Massachusetts
|
+$44.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$766K |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$476K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$362K |
| 4 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$296K |
| 5 |
Deeter Investments
Austin,
Texas
|
-$275K |
ACIU Hedge Fund Activity: Q2 2026 in Review
43 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q2 2026, worth a combined $58.2M — down 16% from $69.2M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ACIU and 6 opened new positions — a net loss of 4 holders — while 16 trimmed existing stakes and 10 added.
The largest buyer was Renaissance Technologies, adding an estimated $594K. The largest seller was Northern Trust, exiting entirely with an estimated $766K sold.
- 43 institutional investors held AC Immune (ACIU) as of Q2 2026, down from 47 in Q1 2026.
- Funds reported $58.2M of AC Immune stock for Q2 2026, down 16% quarter-over-quarter.
- 6 funds opened new AC Immune positions in Q2 2026 and 10 closed out, a net change of -4 holders.
- The largest AC Immune buyer in Q2 2026 was Renaissance Technologies, an estimated $594K added.
- The largest AC Immune seller in Q2 2026 was Northern Trust, an estimated $766K sold.
Based on aggregated 13F filings for Q2 2026.